Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14068304 | 0.89 | LMNA (0.45) | GAAPOLBKMT2AALDH1A1KDM4E | |
| SCHEMBL14025612 | 0.86 | KMT2A (0.48) | GAAPOLBEPHX2MEN1KMT2A | |
| SCHEMBL14025611 | 0.84 | KDM4E (0.50) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL14045823 | 0.81 | GAA (0.43) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14025602 | 0.80 | GAA (0.52) | GAAPOLBEPHX2MEN1KMT2A | |
| SCHEMBL4922921 | 0.78 | CXCR4 (0.54) | POLBMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL28092846 | 0.77 | MEN1 (0.58) | GAAMEN1KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL14025610 | 0.77 | GAA (0.54) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14068453 | 0.76 | CXCR4 (0.44) | GAAALDH1A1KDM4ETDP1 | |
| SCHEMBL4787819 | 0.75 | CXCR4 (0.61) | MEN1KMT2AALDH1A1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | GAA 3192/4885POLB 669/4885EPHX2 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.